Significant association of RANKL polymorphisms with bone metastasis among patients with breast cancer

Objective: polymorphisms with bone metastasis in breast cancer patients. Methods: genetic variants was evaluated by odds ratio (OR) with 95% confidence interval (95%CI). The linkage of two polymorphisms was examined by Haploview. Binary and multivariate logistic analyses were used to optimize the results. Results: < 0.05); they were significantly correlated with the increased risk of bone metastasis occurrence (GG: OR = 2.065, 95%CI=1.104-3.863; G: OR = 1.486, 95%CI=1.068-2.068). Compared with the G-G haplotype, the A-A haplotype was found to significantly reduce the risk of bone metastasis in breast cancer patients (OR = 0.647, 95%CI=0.436-0.959). The multivariate logistic analysis indicated that family history, Ki67, and rs2277438 were positively correlated with bone metastasis, but menopausal state, clinical staging, and rs7325635 were negatively correlated with bone metastasis in breast cancer. Conclusion: rs2277438 variant may be a potential genetic susceptibility factor associated with bone metastasis risk in breast cancer patients, though further functional validation is warranted. Rs7325635 was not independently associated with bone metastasis. The linkage disequilibrium between these two polymorphisms and their combined haplotype effect may play a role in bone metastasis susceptibility.